Enliven Halts HER2 Program, Verastem Gets FDA Nod in Rare Ovarian Cancer, CT Scan Overuse Raises Cancer Risk
Published about 2 months ago • 1 min read
Enliven Therapeutics Halts Phase 1 HER2 Solid Tumor Program
Context: The pursuit of HER2-targeted therapies continues across solid tumors, but achieving a differentiated profile in a crowded space is increasingly difficult.
What's New? Enliven Therapeutics announced it is discontinuing development of its HER2-targeted agent ELVN-002 after internal analyses suggested it would not be competitive with existing therapies in terms of safety, pharmacokinetics, and efficacy.
Why it Matters? The decision reflects heightened selectivity in oncology pipelines and investor pressure for programs that demonstrate clear differentiation early in development.
Read More
|
Verastem Wins FDA Approval for Oral Combo in Low-Grade Serous Ovarian Cancer
Context: Low-grade serous ovarian cancer is a rare, chemo-resistant subtype lacking effective standard therapies.
What's New? The FDA has approved Verastem’s oral combination of adagrasib (a KRAS inhibitor) and trametinib (a MEK inhibitor) for recurrent low-grade serous ovarian cancer, offering a new targeted option for this underserved population.
Why it Matters? This approval marks a meaningful advancement for patients with limited treatment options and validates dual-pathway inhibition as a strategy for difficult gynecologic cancers.
Read More
|
CT Scan Overuse May Contribute to 5% of Future Cancer Cases
Context: While CT scans are a critical diagnostic tool, growing evidence points to the risks of excessive radiation exposure, particularly in asymptomatic or low-risk populations.
What's New? A modeling study suggests that up to 5% of future cancer cases could be attributable to overuse of CT imaging, with younger patients at higher lifetime risk due to cumulative exposure.
Why it Matters? These findings could prompt updated imaging guidelines and heightened awareness among clinicians regarding risk-benefit tradeoffs, especially in non-urgent scenarios.
Read More
|
Anal Cancer Rates Climbing Among Older White and Hispanic Women
Context: While rare, anal cancer incidence is rising, particularly in demographic groups not typically targeted for HPV-related cancer screening.
What's New? A recent epidemiologic study found that White and Hispanic women over 60 are experiencing the fastest increases in anal cancer incidence, suggesting under-recognized vulnerability in these groups.
Why it Matters? The data may warrant revised screening strategies or public health interventions to better address HPV-related cancer risk in aging populations.
Read More
|
|
Oncology Hero
Sharing the latest updates in oncology
Read more from Oncology Hero
Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...
about 1 month ago • 1 min read
Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...
about 1 month ago • 1 min read
Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies. What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies. Why it Matters? This reinforces Itovebi’s growing role in...
about 1 month ago • 1 min read